Mobile Menu
WEBINAR

Proteomics ONLINE

When: December 6, 2022 Time: 3:00 pm

Proteomics is set to play a huge role in the post-genomic era – especially in the context of drug discovery. It is estimated that 85% of the proteome remains “undruggable” – demonstrating masses of unmet potential for interrogating the proteome for novel targets. However, recent advances in proteomics are unlocking more of the proteome, paving the way for a new era of protein-targeting drugs.

Join us in our latest webinar series, Proteomics ONLINE, to explore how the tide is turning for proteomic-driven drug discovery.  

  • Learn how the latest advances in structural proteomics are helping to identify new drug targets.  
  • Understand how high-throughput technologies are helping us identify and quantify novel protein biomarkers, as well as their impact on patient diagnosis and monitoring.  
  • Gain a unique insight into the methods currently being used in the pharmaceutical industry to probe the proteome – and how they’re paving the way for a new era of protein-targeting drugs.  

– – – – –

Webinar 2: Using Advanced Proteomic Techniques to Uncover Novel Biomarkers for Disease

Tuesday 6th December at 3pm GMT/10 am EST/7 am PST 

Join us in webinar two to learn about the latest developments in clinical proteomics and how state-of-the-art technologies are allowing for the high-throughput detection of novel protein biomarkers. Discover the applications of this technology in the clinic and its utility in optimising the drug development pipeline.  

  • Using Advanced Proteomics for Clinical Biomarker Discovery and Quantification   
    • Axel Ducret, Expert Scientist and Group Lead, Roche
  • Olink Proximity Extension Assay: A Novel Affinity Technique for Disease Biomarker Discovery
    • Dale Yuzuki, Director, Olink Proteomics
  • Rationalising Anti-Cancer Drug Responses Using Proteomics and Machine Learning: Towards Next Generation Precision Medicine
    • Pedro Cutillas, Professor of Cell Signalling and Proteomics, Barts Cancer Institute London
  • Using Targeted Proteomics for Multi-Analyte Detection in Clinically Relevant Samples
    • Benedetta Lombardi, Senior Scientist, AstraZeneca

– – – – –

Webinar 3: Drugging the “Undruggable” Proteome 

Tuesday 13th December at 3pm GMT/10 am EST/7 am PST  

Learn how the latest advances in proteomics are allowing drug developers to target more of the proteome. 

  • Using Innovative Methods to Unlock the Undruggable Proteome in the Biopharmaceutical Industry
    • Ashok Dongre, Director and Head of Proteomics, Bristol Myers Squibb 
  • Using Advancements in Protein Folding with Deep Learning to Interrogate the Proteome
    • David Ruau, Head of Strategic Alliances, Drug Discovery AI, NVIDIA
  • Deep Visual Proteomics: An Opportunity to Identify Novel Targets for Drugs and Diagnostics 
    • Andreas Mund, Associate Professor, Novo Nordisk Center for Protein Research 

– – – – –

Previous webinars in this series:

Webinar 1: Leveraging a New Era of Protein Structure Prediction to Advance Proteomic-Driven Drug Discovery 

Tuesday 29th November at 3pm GMT/10 am EST/7 am PST  

Join us in webinar one to explore the most recent advances in structural proteomics and how they are supporting drug target discovery.  

  • Expanding Cross-Linking Based Structural Proteomics Towards Pharmacological Applications
    • Alexander Leitner, Principal Scientist, ETH Zurich
  • Harnessing Integrative Structural Proteomics to Interrogate Protein Dynamics and Interactions 
    •  Antonio Calabrese, Group Lead, University of Leeds

Register for Proteomics ONLINE here:

Speakers

Alexander Leitner Alexander Leitner, Principal Scientist, ETH Zurich

Antonio Calabrese Antonio Calabrese, Group Lead, University of Leeds

Pedro Cutillas Pedro Cutillas, Professor of Cell Signalling and Proteomics, Barts Cancer Institute London

Axel Ducret Axel Ducret, Expert Scientist and Group Lead, Roche

Benedetta Lombardi Benedetta Lombardi, Senior Scientist, AstraZeneca

Dale Yuzuki Dale Yuzuki, Director, Olink Proteomics

Ashok Dongre Ashok Dongre, Director and Head of Proteomics, Bristol Myers Squibb

Andreas Mund Andreas Mund, Associate Professor, Novo Nordisk Center for Protein Research, Copenhagen

David Ruau David Ruau, Head of Strategic Alliances, Drug Discovery AI, NVIDIA

Share this webinar

Article Search